SPONSOR
Sun Yat-sen University
Total Trials
37
Recruiting
37
Phases
Phase 3, Phase 2, Phase 1, Phase 1, Phase 2, Phase 2, Phase 3
Conditions studied: CancerGastric CancerNon-small Cell Lung CancerPediatric Solid TumorColorectal Cancer MetastaticChemotherapyTargeted TherapyImmunotherapyRadiotherapy, Intensity-ModulatedNasopharangeal Cancer
NCT06203314
Recruiting
Epstein-Barr Virus and Cancer Risks
Cancer
NCT05918094 Phase 3
Recruiting
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
NCT05334277 Phase 2
Recruiting
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Non-small Cell Lung Cancer
NCT06760117 Phase 1
Recruiting
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
Pediatric Solid Tumor
NCT06764680 Phase 2
Recruiting
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
Colorectal Cancer Metastatic
NCT07392320 Phase 2
Recruiting
A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma
Nasopharangeal Cancer
NCT07038083
Recruiting
REal-world Data of CARdiometabolic ProtEcTion
Cardiometabolic Diseases
NCT06742502 Phase 2
Recruiting
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
Primary Mediastinal Diffuse Large B-cell Lymphoma
NCT07238881 Phase 2
Recruiting
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
Hepatocellulcar Carcinoma
NCT06517953 Phase 2
Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Non-small Cell Lung Cancer Metastatic
NCT04174079
Recruiting
Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma
Thoracic Esophageal Squamous Cell Carcinoma
NCT07235319 Phase 3
Recruiting
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
Nasopharangeal Cancer
NCT06740370
Recruiting
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
Hepatocellular Carcinoma
NCT06630377
Recruiting
GOS and the Management of Hyperuricemia
Subjects With Hyperuricemia
NCT02966483
Recruiting
Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer
Rectal Neoplasms Malignant
NCT05447169
Recruiting
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
Nasopharyngeal Carcinoma
NCT07065500
Recruiting
Mechanism and Effect of Novel Metabolites on Valvular Heart Disease
Valvular Heart Disease
NCT06669611 Phase 3
Recruiting
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Cancinoma (NPC)
NCT07012954 Phase 1, Phase 2
Recruiting
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Colorectal Cancer Metastatic
NCT05571644 Phase 2
Recruiting
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
Colorectal Cancer
NCT07084662 Phase 2, Phase 3
Recruiting
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
NCT06201065 Phase 3
Recruiting
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Hepatocellular Carcinoma
NCT06760039 Phase 1, Phase 2
Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Diffuse Large B-Cell Lymphoma
NCT05342792 Phase 3
Recruiting
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
NCT06090656 Phase 2
Recruiting
Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)
Hepatocellular Carcinoma
NCT06241612 Phase 3
Recruiting
Individualized Elective Neck Irradiation in NPC Patients
Nasopharyngeal Carcinoma
NCT07389629 Phase 2
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Iparomlimab and Tuvonralimab
NCT01994057
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Non-small Cell Lung Cancer (NSCLC)
NCT07311772 Phase 3
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
Nasopharyngeal Cancinoma (NPC)
NCT05731336
Recruiting
A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
Advanced Colorectal Cancer
NCT06969534 Phase 2
Recruiting
Safety and Efficacy of Pucotenlimab in pLECC
Lymphoepithelioma-like Carcinoma
NCT06569485 Phase 2
Recruiting
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
DLBCL
NCT06657690 Phase 2
Recruiting
Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC
Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT05357846 Phase 3
Recruiting
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Squamous Cell Esophageal Carcinoma
NCT06854250 Phase 2
Recruiting
Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer
Metastatic Prostate Cancer
NCT06313190 Phase 2
Recruiting
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
Hepatocellular Carcinoma
NCT06631391 Phase 1
Recruiting
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
Neuroblastoma